EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
3.1.1.34 | apoC-II | activation of LPL | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.1.1.34 | angiopoietin-like protein 3 | ANGPTL3 causes reduction of the activity of LPL via a two-step mechanism | Homo sapiens | |
3.1.1.34 | angiopoietin-like protein 4 | ANGPTL4 causes reduction of the activity of LPL via a two-step mechanism. The N-terminal coiled-coil domain of human ANGPTL4, residues 26-184, is expressed in Escherichia coli and purified | Homo sapiens | |
3.1.1.34 | apoC-III | inhibits the enzyme's lipolysis activity | Homo sapiens |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.1.1.34 | additional information | - |
additional information | initial rates and kinetics for complete hydrolysis of plasma lipids in postheparin plasma | Homo sapiens |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.1.1.34 | cytoplasm | - |
Homo sapiens | 5737 | - |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.1.1.34 | triacylglycerol + H2O | Homo sapiens | lipoproteins with high triglyceride | diacylglycerol + a carboxylate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.1.1.34 | Homo sapiens | P06858 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.1.1.34 | adipocyte | - |
Homo sapiens | - |
3.1.1.34 | blood plasma | - |
Homo sapiens | - |
3.1.1.34 | endothelium | - |
Homo sapiens | - |
3.1.1.34 | additional information | enzyme LPL is produced and secreted from parenchymal cells like adipocytes and myocytes for transport to the luminal side of the endothelium via interaction with the glycosylphosphatidylinositol-anchored high density lipoprotein binding protein 1 (GPIHBP1) | Homo sapiens | - |
3.1.1.34 | myocyte | - |
Homo sapiens | - |
3.1.1.34 | parenchyma | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.1.1.34 | triacylglycerol + H2O | lipoproteins with high triglyceride | Homo sapiens | diacylglycerol + a carboxylate | - |
? | |
3.1.1.34 | triacylglycerol + H2O | the lipase substrate used is plasma or VLDL with or without added ligands, enzyme source is postheparin plasma, lipoproteins with high triglyceride | Homo sapiens | diacylglycerol + a carboxylate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.1.1.34 | LPL | - |
Homo sapiens |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
3.1.1.34 | 7.4 | - |
assay at | Homo sapiens |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.1.1.34 | additional information | enzyme ligand interaction analysis by isothermal titration calorimetry (ITC) using human plasma as substrate. ITC can be used for quantitative measurements of LPL activity and interactions under in vivo-like conditions, for comparisons of the properties of plasma samples from patients and control subjects as substrates for LPL, as well as for testing of drug candidates, method evaluation, overview | Homo sapiens |
3.1.1.34 | physiological function | the hydrolytic breakdown of plasma triglycerides by LPL at the capillary endothelium is a crucial event that contributes to control of the levels of triglycerides in plasma. LPL hydrolyzes triglycerides in plasma lipoproteins through a complex regulation mechanism | Homo sapiens |